FUNNY

  • Research type

    Research Study

  • Full title

    Targeted heart rate control using the funny current inhibitor ivabradine to reduce morbidity in patients undergoing non-cardiac surgery: a phase IIa, triple blind, placebo controlled randomised trial

  • IRAS ID

    1003561

  • Contact name

    Gareth Ackland

  • Contact email

    g.ackland@qmul.ac.uk

  • Sponsor organisation

    Queen Mary University of London

  • Eudract number

    2020-002099-11

  • ISRCTN Number

    ISRCTN12903789

  • Research summary

    The development of serious medical problems after surgery (e.g. damage to the heart) can adversely affect the patient's care particularly in the
    older more vulnerable population. A poor postoperative outcome not only delays patient recovery but poses longer-term health concerns such as
    loss of mobility and independence. There is a clear and urgent need to improve perioperative care to effectively improve patient outcomes.
    We know patients who are most vulnerable to developing complications often have problems with a specialised nerve that helps control their heart
    beat. A key feature in these patients is a higher heart beat, which is strongly associated with heart damage and coincides with other organs of the
    body not working normally. However current treatments that slow heart rate (e.g. beta-blockers) can result in further damage being done because
    of indirect effects caused by
    these drugs on blood pressure and other functions.
    Our aim is to establish whether the specific lowering of a patient’s heart rate during their perioperative care (the care before, during and after
    surgery) will protect them from damage to the heart and reduce the development of further complications. In this trial, the drug ivabradine will be
    used which slows heart rate only. We will invite 350 patients having surgery that does not involve to take part. We will randomly allocate them (like
    a coin toss) to receive ivabradine tablets or placebo tablets for a maximum of three days from the day of surgery. After surgery, researchers who
    don't know which patients have been given ivabradine will measure their safety and well being.

  • REC name

    London - Westminster Research Ethics Committee

  • REC reference

    21/LO/0069

  • Date of REC Opinion

    4 Jun 2021

  • REC opinion

    Further Information Favourable Opinion